ArticleHealth science reports2026
Anti-PD-1/PD-L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers.Cancers · 2026Review
- PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review).International journal of oncology · 2026Review
- Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.Journal of clinical medicine · 2026Review
- Anti-PD-1/PD-L1 Immunotherapy as a Potential Treatment Option for Lung Cancer: A Perspective Analysis of Opportunities and Challenges.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Anti-PD-1/PD-L1 immunotherapy has changed the treatment landscape of lung cancer. This new approach provides the ability to revitalize the immune system to specifically target and kill cancer cells, thereby creating a new treatment paradigm for patients with non-small cell lung cancer (NSCLC). Methods: In this study, relevant information was extracted from published articles available on PubMed, Scopus, and Google Scholar. The keywords "PD-1", "PD-L1", "Immunotherapy", and "NSCLC" were used to search for relevant information. Results: Despite the promise of durable responses to treatment and overall survival benefits, there are many challenges related to anti-PD-1/PD-L1 therapies, including immune escape, patient heterogeneity, and immune-related side effects. In this study, we discuss the rationale for targeting the PD-1/PD-L1 axis, the complex mechanism of immune activation and resistance, innovative ideas, and future directions for the field to enhance anti-PD-1/PD-L1 outcomes. Conclusion: Investigating resistance mechanisms and developing innovative treatment strategies are essential to optimize the clinical benefits of PD-1/PD-L1 immunotherapy for NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.